Cargando…

Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity

This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolim...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yuji, Kimura, Fuminori, Zheng, Luyi, Kaku, Shoji, Takebayashi, Akie, Kasahara, Kyoko, Tsuji, Shunichiro, Murakami, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Association for Laboratory Animal Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219883/
https://www.ncbi.nlm.nih.gov/pubmed/29937473
http://dx.doi.org/10.1538/expanim.18-0042
_version_ 1783368736020889600
author Tanaka, Yuji
Kimura, Fuminori
Zheng, Luyi
Kaku, Shoji
Takebayashi, Akie
Kasahara, Kyoko
Tsuji, Shunichiro
Murakami, Takashi
author_facet Tanaka, Yuji
Kimura, Fuminori
Zheng, Luyi
Kaku, Shoji
Takebayashi, Akie
Kasahara, Kyoko
Tsuji, Shunichiro
Murakami, Takashi
author_sort Tanaka, Yuji
collection PubMed
description This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolimus (mTORi), and everolimus plus cisplatin (mTORi+Cis). Mice in the Cis and mTORi+Cis groups were intraperitoneally injected with 2 mg/kg of cisplatin for 15 d. Mice in the mTORi and mTORi+Cis groups were orally administered 2.5 mg/kg of everolimus for 29 d, from one week before the first cisplatin injection to one week after the last cisplatin injection. Histological examinations were performed 24 h after the last everolimus administration. The primordial, primary, and antral follicles were significantly depleted in the Cis group compared with that in the control group, confirming the gonadotoxicity of cisplatin. The number of primordial, secondary, and antral follicles was significantly higher in the mTORi+Cis group than in the Cis group, thereby displaying the effect of mTORi-treatment on ovarian protection. Primordial, secondary, and antral follicle counts were similar in the mTORi+Cis and the control groups. The results of this study indicate a protective effect of an mTOR inhibitor against cisplatin chemotherapy-induced gonadotoxicity in the ovarian reserve in an in vivo mouse model.
format Online
Article
Text
id pubmed-6219883
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Japanese Association for Laboratory Animal Science
record_format MEDLINE/PubMed
spelling pubmed-62198832018-11-09 Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity Tanaka, Yuji Kimura, Fuminori Zheng, Luyi Kaku, Shoji Takebayashi, Akie Kasahara, Kyoko Tsuji, Shunichiro Murakami, Takashi Exp Anim Original This study aimed to evaluate the protective effect of everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, on cisplatin chemotherapy-induced ovarian toxicity. Eighty sexually mature, virgin, female, 7-week-old C57BL/6J mice were divided into four groups: control, cisplatin (Cis), everolimus (mTORi), and everolimus plus cisplatin (mTORi+Cis). Mice in the Cis and mTORi+Cis groups were intraperitoneally injected with 2 mg/kg of cisplatin for 15 d. Mice in the mTORi and mTORi+Cis groups were orally administered 2.5 mg/kg of everolimus for 29 d, from one week before the first cisplatin injection to one week after the last cisplatin injection. Histological examinations were performed 24 h after the last everolimus administration. The primordial, primary, and antral follicles were significantly depleted in the Cis group compared with that in the control group, confirming the gonadotoxicity of cisplatin. The number of primordial, secondary, and antral follicles was significantly higher in the mTORi+Cis group than in the Cis group, thereby displaying the effect of mTORi-treatment on ovarian protection. Primordial, secondary, and antral follicle counts were similar in the mTORi+Cis and the control groups. The results of this study indicate a protective effect of an mTOR inhibitor against cisplatin chemotherapy-induced gonadotoxicity in the ovarian reserve in an in vivo mouse model. Japanese Association for Laboratory Animal Science 2018-06-22 2018 /pmc/articles/PMC6219883/ /pubmed/29937473 http://dx.doi.org/10.1538/expanim.18-0042 Text en ©2018 Japanese Association for Laboratory Animal Science This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original
Tanaka, Yuji
Kimura, Fuminori
Zheng, Luyi
Kaku, Shoji
Takebayashi, Akie
Kasahara, Kyoko
Tsuji, Shunichiro
Murakami, Takashi
Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title_full Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title_fullStr Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title_full_unstemmed Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title_short Protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
title_sort protective effect of a mechanistic target of rapamycin inhibitor on an in vivo model ofcisplatin-induced ovarian gonadotoxicity
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219883/
https://www.ncbi.nlm.nih.gov/pubmed/29937473
http://dx.doi.org/10.1538/expanim.18-0042
work_keys_str_mv AT tanakayuji protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT kimurafuminori protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT zhengluyi protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT kakushoji protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT takebayashiakie protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT kasaharakyoko protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT tsujishunichiro protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity
AT murakamitakashi protectiveeffectofamechanistictargetofrapamycininhibitoronaninvivomodelofcisplatininducedovariangonadotoxicity